Literature DB >> 27684192

Co-inhibition of Notch and NF-κB Signaling Pathway Decreases Proliferation through Downregulating IκB-α and Hes-1 Expression in Human Ovarian Cancer OVCAR-3 Cells.

M Majidinia1, E Alizadeh2, B Yousefi1, M Akbarzadeh3, A Mihanfar4, M Rahmati-Yamchi1, N Zarghami1.   

Abstract

Background: Ovarian cancer is one of the most lethal gynecological malignancies and numerous changes in signaling cascades are involved in the initiation and progression of ovarian cancerous cells. Here, we investigated the role of NF-κB and Notch pathways inhibition on human ovarian cancer OVCAR-3 cells proliferation and IκB-α and Hes-1 expression as 2 key genes in these pathways regulation.
Methods: The effects of Bay 11-7085 and DAPT, NF-κB and Notch pathways specific inhibitors, on cell proliferation were evaluated using MTT assay. In addition, the cells were transfected by Notch and IKK-β siRNAs. mRNA and protein levels of target genes were measured by quantitative reverse transcription polymerase chain reaction (qRT-PCR) and western blot after 48 h incubation with inhibitors and siRNAs.
Results: Bay 11-7085 and DAPT significantly decreased the cell proliferation OVCAR-3. IκB-α and Hes-1 mRNA levels decreased to 5 or 3% and 6% or 2% after treatment with Bay 11-7085 or DAPT, respectively (p<0.05). We also found that combination treatment exert a more potent effects on the expression of these gene (p<0.05). Moreover, siRNA transfection caused a significant reduction in IκB-α and Hes-1 mRNA levels (p<0.05). In the protein level, OVCAR-3 cell treatment with both chemichal inhibitors and specific siRNA cause a significant decrease in the expression of target genes (p<0.05)
Conclusion: Our findings suggest that inhibition of NF-κB and Notch signaling pathways can effectively reduce OVCAR-3 cells proliferation. Therefore, pharmacological targeting of the NF-κB and Notch signaling pathway could be a promising future treatment of ovarian cancer. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27684192     DOI: 10.1055/s-0042-115405

Source DB:  PubMed          Journal:  Drug Res (Stuttg)        ISSN: 2194-9379


  7 in total

Review 1.  Targeting IκappaB kinases for cancer therapy.

Authors:  Nikee Awasthee; Vipin Rai; Srinivas Chava; Palanisamy Nallasamy; Ajaikumar B Kunnumakkara; Anupam Bishayee; Subhash C Chauhan; Kishore B Challagundla; Subash C Gupta
Journal:  Semin Cancer Biol       Date:  2018-02-24       Impact factor: 15.707

2.  IL-1R1 deficiency impairs liver regeneration after 2/3 partial hepatectomy in aged mice.

Authors:  Deming Li; Ze Wang; Chunyan Zhang; Cunshuan Xu
Journal:  Turk J Biol       Date:  2021-04-20

Review 3.  Nanotechnology-based advances in the efficient delivery of melatonin.

Authors:  Mohammad Mirza-Aghazadeh-Attari; Ainaz Mihanfar; Bahman Yousefi; Maryam Majidinia
Journal:  Cancer Cell Int       Date:  2022-01-29       Impact factor: 5.722

Review 4.  Exercise and colorectal cancer: prevention and molecular mechanisms.

Authors:  Ramin Amirsasan; Maryam Akbarzadeh; Shabnam Akbarzadeh
Journal:  Cancer Cell Int       Date:  2022-08-09       Impact factor: 6.429

5.  MiR-200c-3p increased HDMEC proliferation through the notch signaling pathway.

Authors:  Xianyu Hu; Suwen Bai; Lingyi Li; Pengfei Tian; Sun Wang; Ning Zhang; Bing Shen; Juan Du; Shengxiu Liu
Journal:  Exp Biol Med (Maywood)       Date:  2021-01-20

6.  Pathway-focused PCR array profiling of CAL-27 cell with over-expressed ZNF750.

Authors:  Li Pan; Hongli Yang; Wenqiang Tang; Cong Xu; Shuangfeng Chen; Zhen Meng; Keyi Li; Haiying Chen
Journal:  Oncotarget       Date:  2017-12-09

7.  Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.

Authors:  Xianxiu Wan; Imran Hussain Chowdhury; Zuliang Jie; Subhadip Choudhuri; Nisha Jain Garg
Journal:  Cells       Date:  2019-12-28       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.